Form PREM14C - Preliminary information statements relating to merger or acquisition:
SEC Accession No. 0001213900-26-005174
Filing Date
2026-01-16
Accepted
2026-01-16 16:35:58
Documents
15
Period of Report
2026-01-16

Document Format Files

Seq Description Document Type Size
1 INFORMATION STATEMENT ea0272926-01.htm PREM14C 11281088
2 FILING FEE IXBRL ea027292601ex-fee_apimeds.htm   iXBRL EX-FILING FEES 11037
3 GRAPHIC tapimeds_logo.jpg GRAPHIC 128942
4 GRAPHIC ttable_01.jpg GRAPHIC 974757
5 GRAPHIC tflowchart_001.jpg GRAPHIC 123378
  Complete submission text file 0001213900-26-005174.txt   13094758

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT ea027292601ex-fee_apimeds_htm.xml XML 3744
Mailing Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747
Business Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747 848-201-5010
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PREM14C | Act: 34 | File No.: 001-42545 | Film No.: 26539966
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)